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ABSTRACT
Gastrointestinal stromal tumors are the most common mesenchymal tumors of the
gastrointestinal tract. Until today, there have been fewmarkers specific for the tumor.
This has complicated the differential diagnosis of the neoplasm from tumors of
smooth muscle origin. Recently, the proto-oncogene c-kit has been shown to be a
very relevant marker as it almost invariably is expressed in gastrointestinal stromal
tumors. Radiation exposure, hormonal and genetic factors, particularly neurofibro-
matosis 2, have been implicated in their development and growth. GIST initiation, ei-
ther in NF2-associated or in sporadic cases, is linked to inactivation of members of
the proteins 4.1 superfamily. Themajority of themutations identified in the NF2 gene
result in a truncated protein and are clinically associated with a severe phenotype.
Occasionally, missense mutations associated with a mild phenotype may occur. We
compared NF2 gene expression in 5 cases with gastrointestinal stromal tumors by
quantitative real-time polymerase chain reaction analysis. NF2 gene mRNA expres-
sion was assessed in fresh tissue of stomach from 5 consecutive patients. We detect-
ed no alterations in NF2 gene expression in the quantitative analyses of the 5 tumors.
Introduction
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tu-
mors of the digestive tract. The constitutive activation of the c-kit proto-oncogene is
a characteristic genetic alteration in GIST, but alterations in chromosomes 14 and 22
may also play a role in the molecular pathogenesis. Radiation exposure, hormonal
and genetic factors, particularly neurofibromatosis 2 (NF2), have been implicated in
their development and growth. GIST initiation, either in NF2-associated or in spo-
radic cases, is linked to inactivation of members of the protein 4.1 superfamily, the
merlin/schwannomin, an NF2 gene product. Precisely, about 10% of sporadic GIST
are caused by loss of heterozygosity (LOH) on chromosome 22q12 of the NF2 tumor
suppressor gene, whereas no causative gene is known for the remaining 40%1-8.
Within the 4.1 superfamily, merlin shares the highest degree of homology with a
subgroup of proteins including ezrin, radixin, andmoesin (ERMproteins), linking the
actin cytoskeleton (by an actin-binding region in the C-terminus) to the cell mem-
brane glycoproteins such as the CD44 glycoprotein (by its N-terminal residues) in po-
larized cells. The N- and C- terminal halves of ERM proteins mutually interact in-
tramolecularly to suppress their binding activities. The C-terminal threonine phos-
phorylation maintains ERM proteins in the active state by suppressing the intramol-
ecular interaction5,7,9,10.
The region of merlin with the greatest structural similarity to the ERM proteins cor-
respond to two-thirds of its N-terminal. The C-terminus of merlin is unique and lacks
the conventional actin-binding region of the ERM proteins but it interacts with F-
actin through the N-terminus5,9,11-14.
The similarity of merlin to the ERM proteins indicates that its functionmight be re-
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lated to those of the ERM proteins: organization of
membrane extensions and cell adhesion, membrane
traffic and cell signaling15. Indeed, merlin interacts, ei-
ther directly or indirectly, with components of cad-
herin-mediated cell junctions and with a number of
proteins that may influence cell growth regulation in-
cluding paxillin, erbB2, p21-activate kinase, and
p535,7,9,10,13 through MDM2 degradation16.
Several experimental studies have demonstrated that
merlin overexpression results in a significant decrease
in cell proliferation, reversion of Ras-induced transfor-
mation, and reduced tumor formation in nude mice. In
contrast, inactivation of the NF2 gene leads to the de-
velopment of cancer through loss of contact-dependent
inhibition of growth13,14,17-20.
Most of the mutations identified in the NF2 gene re-
sult in a truncated protein and are clinically associated
with a severe phenotype. Occasionally, missense muta-
tions associated with a mild phenotype may occur.
In this report, we compare NF2 gene expression in 5
cases of GIST by quantitative reverse-transcriptase
polymerase chain reaction (RT-PCR) analysis. NF2 gene
mRNA expression was assessed in fresh tissue of stom-
ach from 5 consecutive patients. RNA amplification was
assessed by RT-PCR and measured quantitatively. Our
purpose was to further investigate the possible role of
merlin in GIST tumorigenesis and progression.
Methods and results
Tissue specimens were obtained from 5 consecutive
patients affected by GIST surgically treated at the De-
partment of Surgical Pathology (Careggi Hospital, Flo-
rence, Italy) during the period August 2005 to July 2006,
in which fresh tumor tissue was available for RT-PCR
analysis. Two samples were from men and 3 from
women. The average age at the time of the surgery was
54 years.
From each fresh surgical specimen, we selected a
fragment macroscopically representative of the lesion.
Successively, we cut it in half: from 1 half several 5-µm
frozen sections stained with hematoxylin-eosin were
obtained to verify the adequacy of the specimens select-
ed for RT-PCR (presence of pathological tissue only); the
other half was immersed in RNAlater™ (QIAGEN,
Hilden, Germany), so kept overnight at +4 °C, and final-
ly stored at -80 °C until analyzed.
The thawed specimens were cut in small pieces and
homogenized. After proteinase K digestion (250 µg/ml
for 1 h at 37 °C), total RNAwas isolated with 6100 Nucle-
ic Acid PrepStation (manufacturer’s protocol). Total
RNA (500 ng) was subject to reverse transcription to cD-
NA using the High Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA) (manufacturer’s protocol).
We extracted RNA from all samples, and the RNA con-
centration and purity in preparations was quantitated
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spectrophotometrically by measuring their absorbance
at 260 nm and 280 nm. The RNA fragmentation state
was estimated with ethidium bromide-stained 1%
agarose gel.
Real-time quantitative PCR was performed on an ABI
PRISM 7000 SequenceDetector System (Applied Biosys-
tems). PCR products for NF2 were detected using gene-
specific primers and probes labeled with reporter day
FAM (Assay on Demand, Applied Biosystems). GAPDH
was used as endogenous control gene for normaliza-
tion.
PCR reactions were carried out in 96-well plates with
20 µl per well using 1x TaqMan Universal PCR Master-
Mix. After an incubation for 2min at 50 °C and 10min at
95 °C, the reaction continued for 50 cycles at 95 °C for 15
sec and 60 °C for 1 min. The 2–∆∆Ct method described by
Livak et al.21 was used to calculate fold expression levels
relative to the average value of all the RNA specimens.
For each sample of GIST, a specimen of normal mucosa
from the same patient was used as control sample.
NF2 expression in all GIST was compared to the aver-
age value of expression (reference value) of all the be-
nign tissue. The mean of NF2 relative expression of all
GIST showed an expression higher (4.9%) than the aver-
age of all tissue used as calibrator (P = 0.05).
The shift of expression level of NF2 as estimated
through relative RT-PCRwas calculated according to the
Wilcoxon Mann Data analysis was performed using the
SPSS Version 15 (Chicago, IL) statistical package. A P
value ≤0.05 was considered to be statistically significant.
After drawing of the small samples for RT-PCR, the re-
maining tissues were routinely fixed in 10% buffered
formalin and embedded in paraffin. Five-µm-thick sec-
tions were stained with hematoxylin-eosin for the mor-
phological evaluation. A c-kit analysis was performed,
and all cases resulted positive. Diagnostic criteria used
were whose indicated by the most recently revised
World Health Organization (WHO) Classification of gas-
trointestinal stromal tumors.
Discussion
GIST are the most common mesenchymal tumors of
the gastrointestinal tract22. The few markers specific for
GIST has complicated the differential diagnosis of the
neoplasm from tumors of smooth muscle origin. The
proto-oncogene c-kit has been recently shown to be a
very relevantmarker, as it is almost invariably expressed
in GIST23-25. Mutations of the gene are frequently detect-
ed in human GIST, and transfection of the mutant c-kit
into murine lymphoid cells has been shown to induce
malignant transformation. This is evidence that themu-
tation of c-kit may contribute to the tumourigenesis of
GIST24,26. However, as only about half of GIST show c-kit
mutations27-29, alternative mechanisms leading to ma-
lignant transformation of GIST are possible.
Molecular studies have shown that several different
genetic changes occur in GIST. The most frequent alter-
ations in comparative genomic hybridization (CGH)
and LOH studies have been revealed to be losses of
chromosomes 22q and 14q, both in benign and malig-
nant tumors30-32. In line with the CGH results indicating
losses of 22q, both in tumors with high mitotic activity
as well as in tumors with lowmitotic activity, which is an
indicator of potentialmalignancy of these tumors. Inter-
estingly, LOHwas significantlymore frequently detected
in tumors with high mitotic activity. Thus, allelic loss at
these chromosome sitesmay be a common and primary
abnormality responsible for the development of GIST.
We detected no alterations of NF2 gene expression in
the quantitative analyses comprising 5 GIST. However,
NF2 gene mutations were identified in 2 GIST cases in a
study by Fukasawa et al.33, suggesting that NF2 may act
as a tumor suppressor in a subset of these tumors. The
NF2 gene mutations detected occurred independently
of c-kit mutations, since no correlation between NF2
mutations or LOH at 22q and the c-kit mutations was
observed.
Among the aberrant chromosomal regions, the losses
of 9p are of particular interest. Homozygous deletions
were found in 2 GIST cases in the restricted area of 9p
containing the CDKN2A gene34. Since homozygous dele-
tion is one of the known mechanisms for inactivation of
a tumor suppressor gene, it may be possible that inacti-
vation of CDKN2A plays a role in tumorigenesis of GIST,
at least in some cases. In a recent study, chromosomal
changes in GIST were investigated in relation to malig-
nant behavior and the presence of c-kit mutations35.
Interestingly, associations with malignancy, c-kit mu-
tations and loss of chromosome 9 have been detected.
However, only c-kit mutations have been shown to
clearly correlate with malignancy and a poor prognosis
and thus have been proposed to have an important role
as a prognostic factor36.
Several factors contribute to genomic instability, and
cells accumulate many different genetic changes during
carcinogenesis. The multiple forms of genetic changes
may reflect cellular heterogeneity seen within individ-
ual tumors and heterogeneity between tumors of the
same type. This heterogeneity is reflected as differences
in the histological, karyotypic, molecular, physiological
and biochemical factors that can be observed by exam-
ining different parts of the same tumor. In lung cancers,
it has been hypothesized that the heterogeneity of
bronchial tumors may be a consequence of chronic ex-
posure to numerous different carcinogens, e.g., carcino-
gens present in tobacco, which leads to several cell
clones carrying different genetic changes37. This may be
the case with other tumors also associated with envi-
ronmental carcinogen exposure.
Interestingly, many of the genetic alterations detected
in invasive lung tumors have been demonstrated also in
the bronchial epithelium of both current and former
smokers without cancer, indicating that molecular
damage is already present in carcinogen-exposed
bronchial cells38-40. These observations may provide
new methods for the early detection of lung cancer. In
addition, identification of genetic alterations crucial for
the development of lung cancer can be used for cancer
prevention and for the development of novel therapies
specifically targeted to the disrupted cellular activity37.
Recent studies have also highlighted the possibility to
use genetic alterations as early markers since these are
detectable in plasma or serum DNA from cancer pa-
tients, including lung cancer patients37,41-45.
Understanding the interplay between exposure to
specific environmental carcinogens and genetic vari-
ability of important genes will be important for the ulti-
mate goal of comprehending cancer etiology. This new
knowledge will help in the identification of individuals
who are at increased risk of developing cancer and will
hopefully lead to better biomarkers for the early detec-
tion of cancer and cancer prevention. Frequent LOHde-
tected at 22q in GIST, especially in malignant tumors,
suggests that a tumor suppressor gene located at this
chromosomal region is involved in the tumorigenesis of
GIST. However, the absence of NF2 gene mutations and
the presence of merlin in the tumor tissue are evidence
that another, still to be identified gene is responsible for
the development of GIST.
In conclusion, even though studies on larger and ho-
mogeneous series are certainly necessary, this research
can be considered very preliminary to study NF2 ex-
pression in GIST.
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